SecProbe.io

CORRESP
1
filename1.htm

March 5, 2024

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Chris Edwards

    Re:
    Apogee Therapeutics, Inc.

    Registration Statement on Form S-1 (File No. 333-277664)

    Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and
Regulations under the Securities Act of 1933, as amended, please be advised that we will take reasonable steps to secure adequate distribution
of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration
Statement.

We wish to advise you that the participating underwriters
have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange
Act of 1934, as amended.

We hereby join in the request of the registrant
that the effectiveness of the above-captioned Registration Statement be accelerated to 4:00 p.m. Eastern Time, on Thursday, March 7,
2024 or as soon thereafter as practicable.

[Signature page follows]

Very truly yours,

JEFFERIES
LLC

BOFA SECURITIES, INC.

GOLDMAN SACHS & CO. LLC

cowen and company, llc

STIFEL, NICOLAUS &
COMPANY, INCORPORATED

As Representatives of the Underwriters

JEFFERIES
LLC

    By:
    /s/
Matthew Kim

    Name:
    Matthew Kim

    Title:
    Managing Director

    BOFA
    SECURITIES, INC.

    By:
    /s/ Cameron Taylor

    Name:
    Cameron Taylor

    Title:
    Managing Director

    GOLDMAN
    SACHS & CO. LLC

    By:
    /s/ Elizabeth Reed

    Name:
    Elizabeth Reed

    Title:
    Managing Director

    Cowen
    and company, llc

    By:
    /s/ Bill Follis

    Name:
    Bill Follis

    Title:
    Managing Director

    STIFEL,
    NICOLAUS & COMPANY, INCORPORATED

    By:
    /s/
Nick Oust

    Name:
    Nick Oust

    Title:
    Managing Director

[Signature Page to Apogee Therapeutics, Inc.
Acceleration Request]